Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 93 OC35 | DOI: 10.1530/endoabs.93.OC35

1Medical University of Graz, Medical University Graz; DIV. Endocrinology and Metabolism; Endocrinology Lab Platform, Graz, Austria, Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria; 2Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Graz; Department of Obstetrics and Gynaecology, Division of Obstetrics, Medical University of Graz; 3Medical University Graz; DIV. Endocrinology and Metabolism; Endocrinology Lab Platform, Graz, Austria; 4University Hospital Würzburg, Medizinische Klinik I, Division of Endocrinology and Diabetes, Würzburg, Germany; 5Core Unit Clinical Mass Spectrometry, Department of Internal Medicine I, Division of Endocrinology and Diabetology, University Hospital Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, Germany, Endokrinologie, Würzburg, Germany; 6Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz; 7Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Graz, Department of Obstetrics and Gynaecology, Division of Obstetrics, Medical University of Graz; 8Medical University Graz, DIV. Endocrinology and Metabolism, Endocrinology Lab Platform, Graz, Austria.


Background: Preeclampsia (PE) is a serious and complex pregnancy-related condition, characterized by hypertension and endothelial dysfunction, which can potentially damage liver, brain and kidneys, resulting to an increased perinatal morbidity and mortality. We investigated pregnancy-related steroid hormones such as progestogens, estrogens, androgens, and glucocorticoids to assess maternal and fetal development. We aim to compare steroid hormone profiles throughout pregnancy, with and without PE.

Methods: Fourteen pregnant women with PE and 36 normotensive pregnant women were included. Samples were collected at different time points throughout pregnancy (12, 20, 24, 28, 32, 36 weeks of gestational age, WGA), at delivery and 24h postpartum. Steroids were measured in serum by isotope-dilution liquid chromatography tandem mass spectrometry. Steroid-metabolizing enzymes was measured by TaqMan Gene Expression Assays at 24 and 28 WGA.

Results: Pregnant women with PE, showed higher mean values of dehydroepiandrosterone, dehydroepiandrosterone sulfate, testosterone, and androstenedione (P<0.05), while lower mean values of cortisol/cortisone ratio, 11-deoxycortisol, dihydrotestosterone and estradiol (P<0.05) were observed compared to controls. A comparison of substrate-product ratios between pregnant women with and without PE was used to derive candidate genes for steroid-metabolizing enzymes. CYP11B1, CYP17A1 and HSD11B1 showed decreased substrate-product ratios, whereas an increased ratio in SRD5A1, and HSD3B1 were observed (P<0.05). While our qPCR data for CYP11B1, CYP17A1 and HSD11B1 showed higher steroid-related gene expressions in PE compared to controls, the difference was not statistically significant (P>0.05).

Conclusion: In women with PE, we found significantly altered serum steroid levels and substrate-product ratios compared to normotensive pregnant women. Steroid-metabolizing enzymes with decreased product-substrate ratios tended to exhibit higher steroid enzyme expressions in women with PE, but were not statistically significant. Further studies will address the expression profiles of steroid-metabolising enzymes in PE and its expression in placenta tissue to clarify its role as potential biomarker for the prediction of preeclampsia.

Volume 93

ESE Young Endocrinologists and Scientists (EYES) 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.